CytoDyn Inc. (OTCMKTS:CYDY) Files An 8-K Other Events
Item8.01.
| Other Events. |
On March30, 2017, CytoDyn Inc. (the Company) posted an updated
version of the investor presentation deck titled PRO140: First
self-administered antibody therapy for HIV in late-stage clinical
trials to its website at www.cytodyn.com. A copy of the investor
presentation is filed as Exhibit 99.1 to this Form 8-K.
The Company does not intend to incorporate any contents from its
website into this Form 8-K.
| Item9.01. | Financial Statements and Exhibits |
| (d) |
Exhibit No. |
Description. |
||||
| 99.1 | Investor Presentation. |
About CytoDyn Inc. (OTCMKTS:CYDY)
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company’s product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man. CytoDyn Inc. (OTCMKTS:CYDY) Recent Trading Information
CytoDyn Inc. (OTCMKTS:CYDY) closed its last trading session 00.000 at 0.640 with 69,602 shares trading hands.